{"success":true,"data":{"pressRelease":{"id":"26682","rtpr_id":"nBw8tV29la","ticker":"NUS","exchange":"NYSE","all_tickers":["NUS"],"title":"Nu Skin Enterprises Reports First Quarter Results","author":"Business Wire","published_at":"2026-05-07T20:06:00.254Z","article_body":"Nu Skin Enterprises Reports First Quarter Results\n\nNu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter revenue\nresults within its guidance range.\n\nExecutive Summary\n\nQ1 2026 vs. Prior-year Quarter\n Revenue $320.6 million; (12.0)% \n \n \n \n  • +1.1% FX impact or $3.9 million \n Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding \n one-time gain from Mavely sale and other charges \n Customers 669,535; (14)% \n Paid Affiliates 120,850; (8)% \n Sales Leaders 26,915; (13)% \n\n\n“We delivered first quarter revenue in line with our expectations and made\nfurther progress in our strategic priorities while operating in a volatile\nenvironment,” said Ryan Napierski, Nu Skin president and CEO. “As we move\nthrough 2026, we are focused on empowering our sales leaders to scale our\nintelligent wellness platform with our latest innovation, Prysm iO™, ahead\nof our full consumer rollout in the second half. We also continue to invest in\nlaying the groundwork to expand our presence in emerging markets, including\nthe formal launch of India anticipated in late 2026, while continuing to\nimprove our operational discipline to return value to shareholders.\n\n“We are encouraged by early signs of improving paid affiliates and new sales\nleader development in several markets as our leaders begin integrating Prysm\niO into their businesses and continue to build upon our leading anti-aging Tru\nFace® brand. We are focused on partnering with our sales force on leveraging\nthe proprietary nutritional health biomarker tracking from Prysm iO to expand\nthe channel as we prepare to drive customer subscriptions for our wellness\nproducts. While these initiatives will take time to develop, we remain\nconfident that they will increase sales leader engagement and expand our\nglobal reach over time to drive the next phase of growth for Nu Skin.”\n\nQ1 2026 Year-over-year Operating Results\n Revenue $320.6 million compared to $364.5 million \n \n \n \n  • +1.1% FX impact or $3.9 million \n Gross Margin 66.9% or 67.9% excluding certain charges compared to 67.8% \n \n \n \n  • Nu Skin business was 76.9% compared to 76.7% \n Selling Expenses 34.3% compared to 32.5% \n \n \n \n  • Nu Skin business was 40.5% compared to 38.7% \n G&A Expenses 30.7% or 29.9% excluding certain charges compared to 31.1% or 28.9% excluding \n certain charges \n Impairment Expenses $1.8 million impairment compared to $25.1 million impairment \n Operating Margin 1.3% or 3.6% excluding certain charges compared to (2.7)% or 6.4% excluding \n impairment and other charges \n Interest Expense $4.3 million compared to $3.3 million \n Other Income (Expense) $2.8 million compared to $(28.4) million \n \n \n \n • Prior year reflects $28.1 million unrealized loss on investment \n Income Tax Rate 29.4% compared to 20.1% \n EPS $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding \n one-time gain from Mavely sale and other charges  \n\n\nStockholder Value\n Dividend Payments $2.9 million \n Stock Repurchases $5.0 million \n \n \n \n  • $137.3 million remaining in authorization \n\n\nQ2 and Full-year 2026 Outlook\n Q2 2026 Revenue $330 to $360 million; (15)% to (7)% \n \n \n \n  • Approximately 0% FX impact \n Q2 2026 EPS $0.15 to $0.25 \n 2026 Revenue $1.35 to $1.50 billion; (9)% to 1% \n \n \n \n  • Approximately (1)% FX impact \n 2026 EPS $0.70 to $1.10 or $0.80 to $1.20 excluding certain charges \n\n\n“In addition to delivering on revenue and adjusted earnings, we returned $8\nmillion to shareholders in the form of dividends and share repurchases,”\nsaid Chelsea Lantz, interim chief financial officer. “We were also able to\nrefinance our debt, extending our liquidity as we invest in growth initiatives\nand navigate market volatility while executing on our strategy. We are\nmaintaining our annual guidance for 2026 on an adjusted basis. For the second\nquarter, we project revenue between $330 million and $360 million, with\nearnings per share in the range of $0.15 to $0.25.”\n\nConference Call\n\nThe Nu Skin Enterprises management team will host a conference call with the\ninvestment community today at 5 p.m. (ET). Those wishing to access the\nwebcast, as well as the financial information presented during the call, can\nvisit the Investor Relations page on the company's website at ir.nuskin.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2971557-1%26h%3D4001125719%26u%3Dhttp%253A%252F%252Fir.nuskin.com%252Fphoenix.zhtml%253Fc%253D103888%2526p%253Dirol-irhome%26a%3Dir.nuskin.com&esheet=54531434&newsitemid=20260507105655&lan=en-US&anchor=ir.nuskin.com&index=1&md5=ef5158af6dbea09fe0fa4f5d8ade658f)\n. A replay of the webcast will be available on the same page through May 21,\n2026.\n\nAbout Nu Skin Enterprises Inc.\n\nNu Skin Enterprises Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nuskin.com%2F&esheet=54531434&newsitemid=20260507105655&lan=en-US&anchor=Nu+Skin+Enterprises+Inc.&index=2&md5=d35d23e18bc4bc64506ec7985468fccc)\n(NYSE: NUS) is an intelligent beauty and wellness company, powered by a\ndynamic affiliate opportunity platform, which operates in nearly 50 markets\nworldwide. Backed by more than 40 years of scientific research, the\ncompany’s products help people look, feel and live their best with our newly\nintroduced Prysm iO intelligent wellness platform, an award-winning line of\nbeauty device systems and trusted brands in personal care and wellness\nproducts. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed\nin 2018 consisting of synergistic consumer, technology and manufacturing\ncompanies focused on innovation within the beauty, wellness and lifestyle\ncategories.\n\nImportant Information Regarding Forward-Looking Statements: This press release\ncontains forward-looking statements within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange\nAct of 1934, as amended, that represent the company’s current expectations\nand beliefs. All statements other than statements of historical fact are\n“forward-looking statements” for purposes of federal and state securities\nlaws and include, but are not limited to, statements of management’s\nexpectations regarding the company’s performance, growth, initiatives,\nplans, areas of focus, sales force and customers, shareholder value, Prysm\nlaunch and its timing and potential benefits to the business, and emerging\nmarket expansion and its timing; projections regarding revenue, expenses,\nmargins, tax rates, earnings per share, foreign currency fluctuations, uses of\ncash, financial position and other financial items; statements of belief; and\nstatements of assumptions underlying any of the foregoing. In some cases, you\ncan identify these statements by forward-looking words such as “believe,”\n“expect,” “become,” “continue,” “project,” “outlook,”\n“guidance,” “focus,” “expand,” “will,” “would,”\n“could,” “may,” “might,” the negative of these words and other\nsimilar words.\n\nThe forward-looking statements and related assumptions involve risks and\nuncertainties that could cause actual results and outcomes to differ\nmaterially from any forward-looking statements or views expressed herein.\nThese risks and uncertainties include, but are not limited to, the following:\n\n\n * any failure of current or planned initiatives or products to generate interest\namong the company’s sales force and customers and generate sponsoring and\nselling activities on a sustained basis;\n\n * risk that direct selling laws and regulations in any of the company’s\nmarkets, including the United States and Mainland China, may be modified,\ninterpreted or enforced in a manner that results in negative changes to the\ncompany’s business model or negatively impacts its revenue, sales force or\nbusiness, including through the interruption of sales activities, loss of\nlicenses, increased scrutiny of sales force actions, imposition of fines, or\nany other adverse actions or events;\n\n * economic conditions and events globally;\n\n * the company’s future tax-planning initiatives, any prospective or\nretrospective increases in duties or tariffs on the company’s products\nimported into the company’s markets, and any adverse results of tax audits\nor unfavorable changes to tax laws in the company’s various markets;\n\n * competitive pressures in the company’s markets;\n\n * risk that epidemics or other crises, as well as any related disruptions, could\nnegatively impact our business;\n\n * adverse publicity related to the company’s business, products, industry or\nany legal actions or complaints by the company’s sales force or others;\n\n * political, legal, tax and regulatory uncertainties, including trade policies,\nassociated with operating in Mainland China and other international markets;\n\n * uncertainty regarding meeting restrictions and other government scrutiny in\nMainland China, as well as negative media and consumer sentiment in Mainland\nChina on our business operations and results;\n\n * risk of foreign-currency fluctuations and the currency translation impact on\nthe company’s business associated with these fluctuations;\n\n * uncertainties regarding the future financial performance of the businesses the\ncompany has acquired;\n\n * risks related to accurately predicting, delivering or maintaining sufficient\nquantities of products to support planned initiatives or launch strategies,\nand increased risk of inventory write-offs if the company over-forecasts\ndemand for a product or changes its planned initiatives or launch strategies;\nand\n\n * regulatory risks associated with the company’s products, which could require\nthe company to modify its claims or inhibit its ability to import or continue\nselling a product in a market if the product is determined to be a medical\ndevice or if the company is unable to register the product in a timely manner\nunder applicable regulatory requirements.\n\nThe company’s financial performance and the forward-looking statements\ncontained herein are further qualified by a detailed discussion of associated\nrisks set forth in the documents filed by the company with the Securities and\nExchange Commission. The forward-looking statements set forth the company’s\nbeliefs as of the date that such information was first provided, and the\ncompany assumes no duty to update the forward-looking statements contained in\nthis release to reflect any change except as required by law.\n\nNon-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP\nfinancial measure that removes the impact of fluctuations in foreign-currency\nexchange rates, thereby facilitating period-to-period comparisons of the\ncompany’s performance. It is calculated by translating the current\nperiod’s revenue at the same average exchange rates in effect during the\napplicable prior-year period and then comparing that amount to the prior-year\nperiod’s revenue. The company believes that constant-currency revenue change\nis useful to investors, lenders and analysts because such information enables\nthem to gauge the impact of foreign-currency fluctuations on the company’s\nrevenue from period to period.\n\nEarnings per share, gross margin, general and administrative expenses, and\noperating margin, each excluding inventory write-off charges, impairment\nexpense, the gain from the Mavely sale, unrealized investment loss, and/or\nother charges, also are non-GAAP financial measures.\n\n\n * Inventory write-off charges, impairment expense, and unrealized investment\nloss are not part of the ongoing operations of our underlying business; and\n\n * the gain from the Mavely sale, and the other charges incurred in connection\nwith this sale and other corporate actions, are not part of our ongoing\noperations.\n\nThe company believes that these non-GAAP financial measures are useful to\ninvestors, lenders and analysts because removing the impact of these items\nfacilitates period-to-period comparisons of the company’s performance.\nPlease see the reconciliations of these items to our earnings per share, gross\nmargin, operating margin, income tax rate and revenue growth rate calculated\nunder GAAP, below.\n\nThe following table sets forth revenue for the three-month periods ended March\n31, 2026, and 2025 for each of our reportable segments (U.S. dollars in\nthousands):\n   Three Months Ended             Constant-   \n   March 31,             Currency   \n     2026       2025       Change       Change   \n Nu Skin                               \n Americas $ 57,818     $ 69,058       (16.3 )%     (12.6 )% \n Southeast Asia/Pacific   45,474       52,172       (12.8 )%     (16.6 )% \n Mainland China   45,148       47,775       (5.5 )%     (10.0 )% \n Japan   39,739       42,765       (7.1 )%     (4.3 )% \n Europe & Africa   31,218       33,021       (5.5 )%     (14.8 )% \n Hong Kong/Taiwan   27,457       28,447       (3.5 )%     (5.9 )% \n South Korea   25,329       32,515       (22.1 )%     (21.4 )% \n Nu Skin Other   (234 )     529       (144.2 )%     (144.4 )% \n Total Nu Skin   271,949       306,282       (11.2 )%     (12.5 )% \n Rhyz                               \n Manufacturing   44,925       55,290       (18.7 )%     (18.7 )% \n Rhyz Other   3,734       2,918       28.0 %     28.0 % \n Total Rhyz   48,659       58,208       (16.4 )%     (16.4 )% \n Total $ 320,608     $ 364,490       (12.0 )%     (13.1 )% \n\n\nThe following table provides information concerning the number of Customers,\nPaid Affiliates and Sales Leaders in our core Nu Skin business for the\nthree-month periods ended March 31, 2026 and 2025:\n   Three Months Ended         \n   March 31,         \n     2026       2025       Change   \n Customers                       \n Americas   186,448       227,514       (18 )% \n Southeast Asia/Pacific   67,461       74,584       (10 )% \n Mainland China   104,721       122,474       (14 )% \n Japan   102,392       107,742       (5 )% \n Europe & Africa   115,343       130,154       (11 )% \n Hong Kong/Taiwan   35,899       42,523       (16 )% \n South Korea   57,271       71,721       (20 )% \n Total Customers   669,535       776,712       (14 )% \n Paid Affiliates                       \n Americas   27,039       26,936       0 % \n Southeast Asia/Pacific   18,163       22,296       (19 )% \n Mainland China   18,064       19,859       (9 )% \n Japan   19,224       21,073       (9 )% \n Europe & Africa   13,607       15,184       (10 )% \n Hong Kong/Taiwan   9,541       9,622       (1 )% \n South Korea   15,212       16,548       (8 )% \n Total Paid Affiliates   120,850       131,518       (8 )% \n Sales Leaders                       \n Americas   4,930       6,174       (20 )% \n Southeast Asia/Pacific   3,769       4,542       (17 )% \n Mainland China   5,489       6,214       (12 )% \n Japan   5,943       6,210       (4 )% \n Europe & Africa   2,314       2,839       (19 )% \n Hong Kong/Taiwan   2,123       2,207       (4 )% \n South Korea   2,347       2,850       (18 )% \n Total Sales Leaders   26,915       31,036       (13 )% \n\n\n\n * “Customers” are persons who have purchased directly from the Company\nduring the three months ended as of the date indicated. Our Customer numbers\ninclude members of our sales force who made such a purchase, including Paid\nAffiliates and those who qualify as Sales Leaders, but they do not include\nconsumers who purchase directly from members of our sales force.\n\n * “Paid Affiliates” are any Brand Affiliates, as well as members of our\nsales force in Mainland China, who earned sales compensation during the\nthree-month period. In all of our markets besides Mainland China, we refer to\nmembers of our independent sales force as “Brand Affiliates” because their\nprimary role is to promote our brand and products through their personal\nsocial networks.\n\n * “Sales Leaders” are the three-month average of our monthly Brand\nAffiliates, as well as sales employees and independent marketers in Mainland\nChina, who achieved certain qualification requirements as of the end of each\nmonth of the quarter.\n\n \n NU SKIN ENTERPRISES, INC. \n \n \n \nConsolidated Statements of Income (Unaudited) \n \n \n \n(U.S. dollars in thousands, except per share amounts) \n   \n   Three Months Ended \n   March 31, \n     2026       2025   \n Revenue $ 320,608     $ 364,490   \n Cost of sales   106,145       117,529   \n Gross profit   214,463       246,961   \n                 \n Operating expenses:               \n Selling expenses   110,054       118,546   \n General and administrative expenses   98,544       113,204   \n Impairment expenses   1,839       25,114   \n Total operating expenses   210,437       256,864   \n                 \n Operating income (loss)   4,026       (9,903 ) \n Interest expense   4,250       3,283   \n Gain on sale of business   -       176,162   \n Other income (expense), net   2,823       (28,375 ) \n                 \n Income before provision for income taxes   2,599       134,601   \n Provision for income taxes   763       27,086   \n                 \n Net income $ 1,836     $ 107,515   \n                 \n Net income per share:               \n Basic $ 0.04     $ 2.16   \n Diluted $ 0.04     $ 2.14   \n                 \n Weighted-average common shares outstanding (000s):               \n Basic   48,202       49,764   \n Diluted   49,422       50,328   \n   \n\n NU SKIN ENTERPRISES, INC. \n \n \n \nConsolidated Balance Sheets (Unaudited) \n \n \n \n(U.S. dollars in thousands) \n   \n     March 31,       December 31,   \n     2026       2025   \n ASSETS               \n Current assets:               \n Cash and cash equivalents $ 198,654     $ 238,630   \n Current investments   1,751       1,211   \n Accounts receivable, net   45,013       39,544   \n Inventories, net   178,600       178,643   \n Prepaid expenses and other   98,870       89,670   \n Total current assets   522,888       547,698   \n                 \n Property and equipment, net   381,610       377,168   \n Operating lease right-of-use assets   70,350       74,021   \n Goodwill   83,625       83,625   \n Other intangible assets, net   39,290       42,614   \n Other assets   279,035       280,187   \n Total assets   1,376,798       1,405,313   \n                 \n LIABILITIES AND STOCKHOLDERS’ EQUITY               \n Current liabilities:               \n Accounts payable $ 28,815     $ 26,183   \n Accrued expenses   208,182       217,551   \n Current portion of long-term debt   20,000       20,000   \n Total current liabilities   256,997       263,734   \n                 \n Operating lease liabilities   54,017       57,640   \n Long-term debt   203,593       204,187   \n Other liabilities   68,104       74,512   \n Total liabilities   582,711       600,073   \n                 \n Commitments and contingencies               \n                 \n Stockholders’ equity:               \n Class A common stock – 500 million shares authorized, $0.001 par value, 90.6   91       91   \n million shares issued \n Additional paid-in capital   613,890       635,994   \n Treasury stock, at cost – 42.0 million and 42.4 million shares   (1,560,799 )     (1,575,059 ) \n Accumulated other comprehensive loss   (118,377 )     (116,105 ) \n Retained earnings   1,859,282       1,860,319   \n Total stockholders' equity   794,087       805,240   \n Total liabilities and stockholders’ equity $ 1,376,798     $ 1,405,313   \n   \n\n NU SKIN ENTERPRISES, INC. \n \nReconciliation of Gross Margin Excluding Impact of Inventory Write-off to GAAP \n Gross Margin \n \n(in thousands, except for per share amounts) \n                 \n     Three months ended   \n \nMarch 31, \n     2026     2025     \n Gross profit   $ 214,463     $ 246,961     \n Impact of inventory write-off     3,116       -     \n Adjusted gross profit   $ 217,579     $ 246,961     \n                 \n Gross margin     66.9 %     67.8 %   \n Gross margin, excluding inventory write-off impact     67.9 %     67.8 %   \n                 \n Revenue   $ 320,608     $ 364,490     \n   \n\n NU SKIN ENTERPRISES, INC. \n \nReconciliation of General and Administrative Expenses Excluding Certain \n Charges to GAAP General and Administrative Expenses \n \n(in thousands, except for per share amounts) \n                 \n     Three months ended   \n \nMarch 31, \n     2026     2025     \n General and administrative expenses   $ 98,544     $ 113,204     \n Impact of other charges((1))     (2,643 )     (7,966 )   \n Adjusted general and administrative expenses   $ 95,901     $ 105,238     \n                 \n                 \n General and administrative expenses as a percentage of revenue     30.7 %     31.1 %   \n General and administrative expenses as a percentage of revenue, excluding     29.9 %     28.9 %   \n certain charges \n                 \n Revenue   $ 320,608     $ 364,490     \n   \n (1) Other charges for the first quarter of 2026 consist of $1.0 million \n related to the wind down of the separate BeautyBio business and $1.6 million \n of other employee severance charges. Other charges for the first quarter of \n 2025 consist of expenses incurred in connection with the Mavely sale, \n including $2.7 million of transaction bonuses for certain employees and $5.2 \n million of equity compensation as a result of the vesting of the Mavely \n profits interest units. \n   \n\n\n \n NU SKIN ENTERPRISES, INC. \n \nReconciliation of Operating Margin Excluding Certain Charges to GAAP Operating \n Margin \n \n(in thousands, except for per share amounts) \n                 \n     Three months ended   \n \nMarch 31, \n     2026     2025     \n Operating income (loss)   $ 4,026     $ (9,903 )   \n Impact of inventory write-off     3,116       -     \n Impact of other charges((1))     2,643       7,966     \n Impact of impairment     1,839       25,114     \n Adjusted operating income   $ 11,624     $ 23,177     \n                 \n                 \n Operating margin     1.3 %     (2.7 )%   \n Operating margin, excluding certain charges     3.6 %     6.4 %   \n                 \n Revenue   $ 320,608     $ 364,490     \n   \n\n NU SKIN ENTERPRISES, INC. \n \nReconciliation of Earnings Per Share Excluding Impact of Certain Charges to \n GAAP Earnings Per Share \n \n(in thousands, except for per share amounts) \n                 \n     Three months ended   \n \nMarch 31, \n     2026     2025     \n Net income   $ 1,836     $ 107,515     \n Impact of inventory write-off           \n Inventory write-off     3,116       -     \n Tax impact     (1,065 )     -     \n Impact of other charges:               \n Other charges((1))     2,643       7,966     \n Tax impact     (903 )     (725 )   \n Impact of impairment expense:               \n Impairment     1,839       25,114     \n Tax impact     (629 )     (5,433 )   \n Impact of Mavely sale               \n Gain from Mavely sale     -       (176,162 )   \n Tax impact     -       31,104     \n Impact of unrealized investment loss               \n Unrealized investment loss     -       28,077     \n Tax impact     -       (6,074 )   \n Adjusted net income   $ 6,837     $ 11,382     \n                 \n                 \n Diluted earnings per share   $ 0.04     $ 2.14     \n Diluted earnings per share, excluding restructuring impact   $ 0.14     $ 0.23     \n                 \n Weighted-average common shares outstanding (000)     49,422       50,328     \n   \n\n NU SKIN ENTERPRISES, INC. \n \nReconciliation of Earnings Per Share Excluding Impact of Certain Charges to \n GAAP Earnings Per Share \n                 \n     Year ended December 31,   \n     2026 -   2026 -   \n \nLow end \nHigh end \n Earnings Per Share   $ 0.70     $ 1.10     \n Impact of inventory write-off               \n Inventory write-off     0.06       0.06     \n Tax impact     (0.02 )     (0.02 )   \n Impact of other charges               \n Other charges((1))     0.05       0.05     \n Tax impact     (0.02 )     (0.02 )   \n Impact impairment expense:               \n Impairment     0.04       0.04     \n Tax impact     (0.01 )     (0.01 )   \n Adjusted EPS   $ 0.80     $ 1.20     \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260507105655/en/\n(https://www.businesswire.com/news/home/20260507105655/en/)\n\nMedia: media@nuskin.com (mailto:media@nuskin.com) , (801) 345-6397\n\nInvestors: investorrelations@nuskin.com (mailto:investorrelations@nuskin.com)\n, (801) 345-3577\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw8tV29la","title":"Nu Skin Enterprises Reports First Quarter Results","author":"Business Wire","ticker":"NUS","created":"2026-05-07T20:06:00.254Z","tickers":["NUS"],"exchange":"NYSE","article_body":"Nu Skin Enterprises Reports First Quarter Results\n\nNu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter revenue\nresults within its guidance range.\n\nExecutive Summary\n\nQ1 2026 vs. Prior-year Quarter\n Revenue $320.6 million; (12.0)% \n \n \n \n  • +1.1% FX impact or $3.9 million \n Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding \n one-time gain from Mavely sale and other charges \n Customers 669,535; (14)% \n Paid Affiliates 120,850; (8)% \n Sales Leaders 26,915; (13)% \n\n\n“We delivered first quarter revenue in line with our expectations and made\nfurther progress in our strategic priorities while operating in a volatile\nenvironment,” said Ryan Napierski, Nu Skin president and CEO. “As we move\nthrough 2026, we are focused on empowering our sales leaders to scale our\nintelligent wellness platform with our latest innovation, Prysm iO™, ahead\nof our full consumer rollout in the second half. We also continue to invest in\nlaying the groundwork to expand our presence in emerging markets, including\nthe formal launch of India anticipated in late 2026, while continuing to\nimprove our operational discipline to return value to shareholders.\n\n“We are encouraged by early signs of improving paid affiliates and new sales\nleader development in several markets as our leaders begin integrating Prysm\niO into their businesses and continue to build upon our leading anti-aging Tru\nFace® brand. We are focused on partnering with our sales force on leveraging\nthe proprietary nutritional health biomarker tracking from Prysm iO to expand\nthe channel as we prepare to drive customer subscriptions for our wellness\nproducts. While these initiatives will take time to develop, we remain\nconfident that they will increase sales leader engagement and expand our\nglobal reach over time to drive the next phase of growth for Nu Skin.”\n\nQ1 2026 Year-over-year Operating Results\n Revenue $320.6 million compared to $364.5 million \n \n \n \n  • +1.1% FX impact or $3.9 million \n Gross Margin 66.9% or 67.9% excluding certain charges compared to 67.8% \n \n \n \n  • Nu Skin business was 76.9% compared to 76.7% \n Selling Expenses 34.3% compared to 32.5% \n \n \n \n  • Nu Skin business was 40.5% compared to 38.7% \n G&A Expenses 30.7% or 29.9% excluding certain charges compared to 31.1% or 28.9% excluding \n certain charges \n Impairment Expenses $1.8 million impairment compared to $25.1 million impairment \n Operating Margin 1.3% or 3.6% excluding certain charges compared to (2.7)% or 6.4% excluding \n impairment and other charges \n Interest Expense $4.3 million compared to $3.3 million \n Other Income (Expense) $2.8 million compared to $(28.4) million \n \n \n \n • Prior year reflects $28.1 million unrealized loss on investment \n Income Tax Rate 29.4% compared to 20.1% \n EPS $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding \n one-time gain from Mavely sale and other charges  \n\n\nStockholder Value\n Dividend Payments $2.9 million \n Stock Repurchases $5.0 million \n \n \n \n  • $137.3 million remaining in authorization \n\n\nQ2 and Full-year 2026 Outlook\n Q2 2026 Revenue $330 to $360 million; (15)% to (7)% \n \n \n \n  • Approximately 0% FX impact \n Q2 2026 EPS $0.15 to $0.25 \n 2026 Revenue $1.35 to $1.50 billion; (9)% to 1% \n \n \n \n  • Approximately (1)% FX impact \n 2026 EPS $0.70 to $1.10 or $0.80 to $1.20 excluding certain charges \n\n\n“In addition to delivering on revenue and adjusted earnings, we returned $8\nmillion to shareholders in the form of dividends and share repurchases,”\nsaid Chelsea Lantz, interim chief financial officer. “We were also able to\nrefinance our debt, extending our liquidity as we invest in growth initiatives\nand navigate market volatility while executing on our strategy. We are\nmaintaining our annual guidance for 2026 on an adjusted basis. For the second\nquarter, we project revenue between $330 million and $360 million, with\nearnings per share in the range of $0.15 to $0.25.”\n\nConference Call\n\nThe Nu Skin Enterprises management team will host a conference call with the\ninvestment community today at 5 p.m. (ET). Those wishing to access the\nwebcast, as well as the financial information presented during the call, can\nvisit the Investor Relations page on the company's website at ir.nuskin.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2971557-1%26h%3D4001125719%26u%3Dhttp%253A%252F%252Fir.nuskin.com%252Fphoenix.zhtml%253Fc%253D103888%2526p%253Dirol-irhome%26a%3Dir.nuskin.com&esheet=54531434&newsitemid=20260507105655&lan=en-US&anchor=ir.nuskin.com&index=1&md5=ef5158af6dbea09fe0fa4f5d8ade658f)\n. A replay of the webcast will be available on the same page through May 21,\n2026.\n\nAbout Nu Skin Enterprises Inc.\n\nNu Skin Enterprises Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nuskin.com%2F&esheet=54531434&newsitemid=20260507105655&lan=en-US&anchor=Nu+Skin+Enterprises+Inc.&index=2&md5=d35d23e18bc4bc64506ec7985468fccc)\n(NYSE: NUS) is an intelligent beauty and wellness company, powered by a\ndynamic affiliate opportunity platform, which operates in nearly 50 markets\nworldwide. Backed by more than 40 years of scientific research, the\ncompany’s products help people look, feel and live their best with our newly\nintroduced Prysm iO intelligent wellness platform, an award-winning line of\nbeauty device systems and trusted brands in personal care and wellness\nproducts. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed\nin 2018 consisting of synergistic consumer, technology and manufacturing\ncompanies focused on innovation within the beauty, wellness and lifestyle\ncategories.\n\nImportant Information Regarding Forward-Looking Statements: This press release\ncontains forward-looking statements within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange\nAct of 1934, as amended, that represent the company’s current expectations\nand beliefs. All statements other than statements of historical fact are\n“forward-looking statements” for purposes of federal and state securities\nlaws and include, but are not limited to, statements of management’s\nexpectations regarding the company’s performance, growth, initiatives,\nplans, areas of focus, sales force and customers, shareholder value, Prysm\nlaunch and its timing and potential benefits to the business, and emerging\nmarket expansion and its timing; projections regarding revenue, expenses,\nmargins, tax rates, earnings per share, foreign currency fluctuations, uses of\ncash, financial position and other financial items; statements of belief; and\nstatements of assumptions underlying any of the foregoing. In some cases, you\ncan identify these statements by forward-looking words such as “believe,”\n“expect,” “become,” “continue,” “project,” “outlook,”\n“guidance,” “focus,” “expand,” “will,” “would,”\n“could,” “may,” “might,” the negative of these words and other\nsimilar words.\n\nThe forward-looking statements and related assumptions involve risks and\nuncertainties that could cause actual results and outcomes to differ\nmaterially from any forward-looking statements or views expressed herein.\nThese risks and uncertainties include, but are not limited to, the following:\n\n\n * any failure of current or planned initiatives or products to generate interest\namong the company’s sales force and customers and generate sponsoring and\nselling activities on a sustained basis;\n\n * risk that direct selling laws and regulations in any of the company’s\nmarkets, including the United States and Mainland China, may be modified,\ninterpreted or enforced in a manner that results in negative changes to the\ncompany’s business model or negatively impacts its revenue, sales force or\nbusiness, including through the interruption of sales activities, loss of\nlicenses, increased scrutiny of sales force actions, imposition of fines, or\nany other adverse actions or events;\n\n * economic conditions and events globally;\n\n * the company’s future tax-planning initiatives, any prospective or\nretrospective increases in duties or tariffs on the company’s products\nimported into the company’s markets, and any adverse results of tax audits\nor unfavorable changes to tax laws in the company’s various markets;\n\n * competitive pressures in the company’s markets;\n\n * risk that epidemics or other crises, as well as any related disruptions, could\nnegatively impact our business;\n\n * adverse publicity related to the company’s business, products, industry or\nany legal actions or complaints by the company’s sales force or others;\n\n * political, legal, tax and regulatory uncertainties, including trade policies,\nassociated with operating in Mainland China and other international markets;\n\n * uncertainty regarding meeting restrictions and other government scrutiny in\nMainland China, as well as negative media and consumer sentiment in Mainland\nChina on our business operations and results;\n\n * risk of foreign-currency fluctuations and the currency translation impact on\nthe company’s business associated with these fluctuations;\n\n * uncertainties regarding the future financial performance of the businesses the\ncompany has acquired;\n\n * risks related to accurately predicting, delivering or maintaining sufficient\nquantities of products to support planned initiatives or launch strategies,\nand increased risk of inventory write-offs if the company over-forecasts\ndemand for a product or changes its planned initiatives or launch strategies;\nand\n\n * regulatory risks associated with the company’s products, which could require\nthe company to modify its claims or inhibit its ability to import or continue\nselling a product in a market if the product is determined to be a medical\ndevice or if the company is unable to register the product in a timely manner\nunder applicable regulatory requirements.\n\nThe company’s financial performance and the forward-looking statements\ncontained herein are further qualified by a detailed discussion of associated\nrisks set forth in the documents filed by the company with the Securities and\nExchange Commission. The forward-looking statements set forth the company’s\nbeliefs as of the date that such information was first provided, and the\ncompany assumes no duty to update the forward-looking statements contained in\nthis release to reflect any change except as required by law.\n\nNon-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP\nfinancial measure that removes the impact of fluctuations in foreign-currency\nexchange rates, thereby facilitating period-to-period comparisons of the\ncompany’s performance. It is calculated by translating the current\nperiod’s revenue at the same average exchange rates in effect during the\napplicable prior-year period and then comparing that amount to the prior-year\nperiod’s revenue. The company believes that constant-currency revenue change\nis useful to investors, lenders and analysts because such information enables\nthem to gauge the impact of foreign-currency fluctuations on the company’s\nrevenue from period to period.\n\nEarnings per share, gross margin, general and administrative expenses, and\noperating margin, each excluding inventory write-off charges, impairment\nexpense, the gain from the Mavely sale, unrealized investment loss, and/or\nother charges, also are non-GAAP financial measures.\n\n\n * Inventory write-off charges, impairment expense, and unrealized investment\nloss are not part of the ongoing operations of our underlying business; and\n\n * the gain from the Mavely sale, and the other charges incurred in connection\nwith this sale and other corporate actions, are not part of our ongoing\noperations.\n\nThe company believes that these non-GAAP financial measures are useful to\ninvestors, lenders and analysts because removing the impact of these items\nfacilitates period-to-period comparisons of the company’s performance.\nPlease see the reconciliations of these items to our earnings per share, gross\nmargin, operating margin, income tax rate and revenue growth rate calculated\nunder GAAP, below.\n\nThe following table sets forth revenue for the three-month periods ended March\n31, 2026, and 2025 for each of our reportable segments (U.S. dollars in\nthousands):\n   Three Months Ended             Constant-   \n   March 31,             Currency   \n     2026       2025       Change       Change   \n Nu Skin                               \n Americas $ 57,818     $ 69,058       (16.3 )%     (12.6 )% \n Southeast Asia/Pacific   45,474       52,172       (12.8 )%     (16.6 )% \n Mainland China   45,148       47,775       (5.5 )%     (10.0 )% \n Japan   39,739       42,765       (7.1 )%     (4.3 )% \n Europe & Africa   31,218       33,021       (5.5 )%     (14.8 )% \n Hong Kong/Taiwan   27,457       28,447       (3.5 )%     (5.9 )% \n South Korea   25,329       32,515       (22.1 )%     (21.4 )% \n Nu Skin Other   (234 )     529       (144.2 )%     (144.4 )% \n Total Nu Skin   271,949       306,282       (11.2 )%     (12.5 )% \n Rhyz                               \n Manufacturing   44,925       55,290       (18.7 )%     (18.7 )% \n Rhyz Other   3,734       2,918       28.0 %     28.0 % \n Total Rhyz   48,659       58,208       (16.4 )%     (16.4 )% \n Total $ 320,608     $ 364,490       (12.0 )%     (13.1 )% \n\n\nThe following table provides information concerning the number of Customers,\nPaid Affiliates and Sales Leaders in our core Nu Skin business for the\nthree-month periods ended March 31, 2026 and 2025:\n   Three Months Ended         \n   March 31,         \n     2026       2025       Change   \n Customers                       \n Americas   186,448       227,514       (18 )% \n Southeast Asia/Pacific   67,461       74,584       (10 )% \n Mainland China   104,721       122,474       (14 )% \n Japan   102,392       107,742       (5 )% \n Europe & Africa   115,343       130,154       (11 )% \n Hong Kong/Taiwan   35,899       42,523       (16 )% \n South Korea   57,271       71,721       (20 )% \n Total Customers   669,535       776,712       (14 )% \n Paid Affiliates                       \n Americas   27,039       26,936       0 % \n Southeast Asia/Pacific   18,163       22,296       (19 )% \n Mainland China   18,064       19,859       (9 )% \n Japan   19,224       21,073       (9 )% \n Europe & Africa   13,607       15,184       (10 )% \n Hong Kong/Taiwan   9,541       9,622       (1 )% \n South Korea   15,212       16,548       (8 )% \n Total Paid Affiliates   120,850       131,518       (8 )% \n Sales Leaders                       \n Americas   4,930       6,174       (20 )% \n Southeast Asia/Pacific   3,769       4,542       (17 )% \n Mainland China   5,489       6,214       (12 )% \n Japan   5,943       6,210       (4 )% \n Europe & Africa   2,314       2,839       (19 )% \n Hong Kong/Taiwan   2,123       2,207       (4 )% \n South Korea   2,347       2,850       (18 )% \n Total Sales Leaders   26,915       31,036       (13 )% \n\n\n\n * “Customers” are persons who have purchased directly from the Company\nduring the three months ended as of the date indicated. Our Customer numbers\ninclude members of our sales force who made such a purchase, including Paid\nAffiliates and those who qualify as Sales Leaders, but they do not include\nconsumers who purchase directly from members of our sales force.\n\n * “Paid Affiliates” are any Brand Affiliates, as well as members of our\nsales force in Mainland China, who earned sales compensation during the\nthree-month period. In all of our markets besides Mainland China, we refer to\nmembers of our independent sales force as “Brand Affiliates” because their\nprimary role is to promote our brand and products through their personal\nsocial networks.\n\n * “Sales Leaders” are the three-month average of our monthly Brand\nAffiliates, as well as sales employees and independent marketers in Mainland\nChina, who achieved certain qualification requirements as of the end of each\nmonth of the quarter.\n\n \n NU SKIN ENTERPRISES, INC. \n \n \n \nConsolidated Statements of Income (Unaudited) \n \n \n \n(U.S. dollars in thousands, except per share amounts) \n   \n   Three Months Ended \n   March 31, \n     2026       2025   \n Revenue $ 320,608     $ 364,490   \n Cost of sales   106,145       117,529   \n Gross profit   214,463       246,961   \n                 \n Operating expenses:               \n Selling expenses   110,054       118,546   \n General and administrative expenses   98,544       113,204   \n Impairment expenses   1,839       25,114   \n Total operating expenses   210,437       256,864   \n                 \n Operating income (loss)   4,026       (9,903 ) \n Interest expense   4,250       3,283   \n Gain on sale of business   -       176,162   \n Other income (expense), net   2,823       (28,375 ) \n                 \n Income before provision for income taxes   2,599       134,601   \n Provision for income taxes   763       27,086   \n                 \n Net income $ 1,836     $ 107,515   \n                 \n Net income per share:               \n Basic $ 0.04     $ 2.16   \n Diluted $ 0.04     $ 2.14   \n                 \n Weighted-average common shares outstanding (000s):               \n Basic   48,202       49,764   \n Diluted   49,422       50,328   \n   \n\n NU SKIN ENTERPRISES, INC. \n \n \n \nConsolidated Balance Sheets (Unaudited) \n \n \n \n(U.S. dollars in thousands) \n   \n     March 31,       December 31,   \n     2026       2025   \n ASSETS               \n Current assets:               \n Cash and cash equivalents $ 198,654     $ 238,630   \n Current investments   1,751       1,211   \n Accounts receivable, net   45,013       39,544   \n Inventories, net   178,600       178,643   \n Prepaid expenses and other   98,870       89,670   \n Total current assets   522,888       547,698   \n                 \n Property and equipment, net   381,610       377,168   \n Operating lease right-of-use assets   70,350       74,021   \n Goodwill   83,625       83,625   \n Other intangible assets, net   39,290       42,614   \n Other assets   279,035       280,187   \n Total assets   1,376,798       1,405,313   \n                 \n LIABILITIES AND STOCKHOLDERS’ EQUITY               \n Current liabilities:               \n Accounts payable $ 28,815     $ 26,183   \n Accrued expenses   208,182       217,551   \n Current portion of long-term debt   20,000       20,000   \n Total current liabilities   256,997       263,734   \n                 \n Operating lease liabilities   54,017       57,640   \n Long-term debt   203,593       204,187   \n Other liabilities   68,104       74,512   \n Total liabilities   582,711       600,073   \n                 \n Commitments and contingencies               \n                 \n Stockholders’ equity:               \n Class A common stock – 500 million shares authorized, $0.001 par value, 90.6   91       91   \n million shares issued \n Additional paid-in capital   613,890       635,994   \n Treasury stock, at cost – 42.0 million and 42.4 million shares   (1,560,799 )     (1,575,059 ) \n Accumulated other comprehensive loss   (118,377 )     (116,105 ) \n Retained earnings   1,859,282       1,860,319   \n Total stockholders' equity   794,087       805,240   \n Total liabilities and stockholders’ equity $ 1,376,798     $ 1,405,313   \n   \n\n NU SKIN ENTERPRISES, INC. \n \nReconciliation of Gross Margin Excluding Impact of Inventory Write-off to GAAP \n Gross Margin \n \n(in thousands, except for per share amounts) \n                 \n     Three months ended   \n \nMarch 31, \n     2026     2025     \n Gross profit   $ 214,463     $ 246,961     \n Impact of inventory write-off     3,116       -     \n Adjusted gross profit   $ 217,579     $ 246,961     \n                 \n Gross margin     66.9 %     67.8 %   \n Gross margin, excluding inventory write-off impact     67.9 %     67.8 %   \n                 \n Revenue   $ 320,608     $ 364,490     \n   \n\n NU SKIN ENTERPRISES, INC. \n \nReconciliation of General and Administrative Expenses Excluding Certain \n Charges to GAAP General and Administrative Expenses \n \n(in thousands, except for per share amounts) \n                 \n     Three months ended   \n \nMarch 31, \n     2026     2025     \n General and administrative expenses   $ 98,544     $ 113,204     \n Impact of other charges((1))     (2,643 )     (7,966 )   \n Adjusted general and administrative expenses   $ 95,901     $ 105,238     \n                 \n                 \n General and administrative expenses as a percentage of revenue     30.7 %     31.1 %   \n General and administrative expenses as a percentage of revenue, excluding     29.9 %     28.9 %   \n certain charges \n                 \n Revenue   $ 320,608     $ 364,490     \n   \n (1) Other charges for the first quarter of 2026 consist of $1.0 million \n related to the wind down of the separate BeautyBio business and $1.6 million \n of other employee severance charges. Other charges for the first quarter of \n 2025 consist of expenses incurred in connection with the Mavely sale, \n including $2.7 million of transaction bonuses for certain employees and $5.2 \n million of equity compensation as a result of the vesting of the Mavely \n profits interest units. \n   \n\n\n \n NU SKIN ENTERPRISES, INC. \n \nReconciliation of Operating Margin Excluding Certain Charges to GAAP Operating \n Margin \n \n(in thousands, except for per share amounts) \n                 \n     Three months ended   \n \nMarch 31, \n     2026     2025     \n Operating income (loss)   $ 4,026     $ (9,903 )   \n Impact of inventory write-off     3,116       -     \n Impact of other charges((1))     2,643       7,966     \n Impact of impairment     1,839       25,114     \n Adjusted operating income   $ 11,624     $ 23,177     \n                 \n                 \n Operating margin     1.3 %     (2.7 )%   \n Operating margin, excluding certain charges     3.6 %     6.4 %   \n                 \n Revenue   $ 320,608     $ 364,490     \n   \n\n NU SKIN ENTERPRISES, INC. \n \nReconciliation of Earnings Per Share Excluding Impact of Certain Charges to \n GAAP Earnings Per Share \n \n(in thousands, except for per share amounts) \n                 \n     Three months ended   \n \nMarch 31, \n     2026     2025     \n Net income   $ 1,836     $ 107,515     \n Impact of inventory write-off           \n Inventory write-off     3,116       -     \n Tax impact     (1,065 )     -     \n Impact of other charges:               \n Other charges((1))     2,643       7,966     \n Tax impact     (903 )     (725 )   \n Impact of impairment expense:               \n Impairment     1,839       25,114     \n Tax impact     (629 )     (5,433 )   \n Impact of Mavely sale               \n Gain from Mavely sale     -       (176,162 )   \n Tax impact     -       31,104     \n Impact of unrealized investment loss               \n Unrealized investment loss     -       28,077     \n Tax impact     -       (6,074 )   \n Adjusted net income   $ 6,837     $ 11,382     \n                 \n                 \n Diluted earnings per share   $ 0.04     $ 2.14     \n Diluted earnings per share, excluding restructuring impact   $ 0.14     $ 0.23     \n                 \n Weighted-average common shares outstanding (000)     49,422       50,328     \n   \n\n NU SKIN ENTERPRISES, INC. \n \nReconciliation of Earnings Per Share Excluding Impact of Certain Charges to \n GAAP Earnings Per Share \n                 \n     Year ended December 31,   \n     2026 -   2026 -   \n \nLow end \nHigh end \n Earnings Per Share   $ 0.70     $ 1.10     \n Impact of inventory write-off               \n Inventory write-off     0.06       0.06     \n Tax impact     (0.02 )     (0.02 )   \n Impact of other charges               \n Other charges((1))     0.05       0.05     \n Tax impact     (0.02 )     (0.02 )   \n Impact impairment expense:               \n Impairment     0.04       0.04     \n Tax impact     (0.01 )     (0.01 )   \n Adjusted EPS   $ 0.80     $ 1.20     \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260507105655/en/\n(https://www.businesswire.com/news/home/20260507105655/en/)\n\nMedia: media@nuskin.com (mailto:media@nuskin.com) , (801) 345-6397\n\nInvestors: investorrelations@nuskin.com (mailto:investorrelations@nuskin.com)\n, (801) 345-3577\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-07T20:06:00.315363208Z","server_sent_at_ms":1778184360315},"received_at":"2026-05-07T20:06:00.582Z","source_url":"https://www.businesswire.com/news/home/20260507105655/en/"},"analysis":null,"durationMs":null,"modelName":null}}